Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Michael Richard Verneris

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Verneris, Michael

One or more keywords matched the following properties of Verneris, Michael

Property	Value
overview	Our laboratory is focused on using the immune system to target and treat cancer. Active projects in the laboratory include: 1) Chimeric antigen receptor expressing T cell (CART) homing to solid tumors 2) Chimeric antigen receptor expressing iPS and ES cells that are differentiated into natural killer (NK) and T cells 3) Animal models of bone marrow transplantation

One or more keywords matched the following items that are connected to Verneris, Michael

Item Type	Name
Concept	CD56 Antigen
Concept	Receptors, Antigen, T-Cell
Academic Article	Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation.
Academic Article	Natural killer-cell differentiation by myeloid progenitors.
Academic Article	Cytotoxic T-lymphocyte antigen-4 single nucleotide polymorphisms are not associated with outcomes after unrelated donor transplantation: a center for international blood and marrow transplant research analysis.
Academic Article	Development of IL-22-producing NK lineage cells from umbilical cord blood hematopoietic stem cells in the absence of secondary lymphoid tissue.
Academic Article	Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods.
Academic Article	Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) NK cells are transplantable and expand in vivo in response to recipient CMV antigen.
Academic Article	The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.
Academic Article	Lineage relationships of human interleukin-22-producing CD56+ ROR?t+ innate lymphoid cells and conventional natural killer cells.
Academic Article	CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases.
Academic Article	CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.
Academic Article	Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis.
Academic Article	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research.
Academic Article	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts.
Grant	Genetic epidemiology of hematopoietic cell transplant outcomes
Grant	Lymphoid Tissue Inducer/NK22 Cells and Post-transplant Immune Recovery
Academic Article	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Academic Article	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Concept	CD48 Antigen
Concept	CTLA-4 Antigen
Concept	CD52 Antigen
Academic Article	Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage.
Academic Article	Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling.
Academic Article	Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
Academic Article	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia.
Academic Article	Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
Academic Article	Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
Academic Article	Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.
Academic Article	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.
Academic Article	Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Academic Article	Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Academic Article	Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Academic Article	Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Academic Article	HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Academic Article	Practice Preferences for Consolidative Hematopoietic Stem Cell Transplantation Following Tisagenlecleucel in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia.

Search Criteria

H Y Antigen